MoleculeMind

The core of MoleculeMind's offering is its proprietary AI-driven platform, "MoleculeOS". This integrated system leverages data-driven deep learning algorithms to accelerate the discovery, optimization, and design of large molecules like proteins. The platform is engineered to make the process of developing large-molecule drugs more predictable and programmable, thereby enhancing efficiency. The business model centers on providing this platform to clients in biopharmaceuticals and synthetic biology, helping them to more rapidly identify, modify, and generate ideal proteins for their specific needs. The company targets a wide range of applications, including the development of innovative drugs (peptides, antibodies), industrial enzyme optimization, advanced materials, and sustainable agriculture. Through partnerships with pharmaceutical companies and national laboratories, MoleculeMind is applying its technology to optimize industrial enzymes and has achieved notable results in designing proteins for anti-tumor therapies.

Since its inception, MoleculeMind has secured significant venture capital backing. After a seed round in April 2022, the company announced a strategic investment of over 100 million yuan in February 2023. This was followed by a Series A round in September 2024, which raised several hundred million yuan more, co-led by Cherami Investment and Shenzhen Capital Group. These funds are allocated towards expanding the company's expert team—which already includes talent from top universities and companies like MIT, Tsinghua University, Meta, and Baidu—and advancing the industrial application of its AI protein technologies.